Longevity

In 2025, GLP-1 drugs move beyond weight loss into validated risk reduction. Regulators, outcomes trials, and insurers now point to survival and organ protection as the main story.

A 2025 Molecular Therapy study reported that a single AAV dose elevating secreted Klotho extended male mouse lifespan by roughly 15 to 20 percent and improved aging markers. Here is a concrete, risk-aware plan to reach early human trials, with routes, biomarkers, and go or no go gates.

The FDA has cleared the first U.S. human trials of gene-edited pig kidneys. We unpack the 10 to 69 genomic edits, the new anti-rejection regimens, and the biosecure pig herds that could finally end the kidney shortage.

ESC 2025 data show low-dose colchicine can slow TET2-driven clonal growth, while new mega-cohort analyses pinpoint who is at risk. Here is why routine CHIP screening is near and how a 12–24 month rollout could work.

Two signals in 2025 mark a new era in cholesterol care. AHA VESALIUS-CV shows PCSK9 inhibitors prevent first cardiovascular events, and early Heart-2 data for VERVE-102 suggests single-infusion, durable LDL reductions following Lilly’s Verve acquisition.

After the FDA’s September 2025 clarification that NMN is lawful in supplements, the NAD+ space has a narrow window to trade sizzle for substance. This roadmap lays out the evidence plan, quality playbook, and retail relisting strategy needed to make NAD repletion real.

Mouse data put anti-glycation upstream of multiple hallmarks. Here is what Gly-Low changes, how to design a human trial, what to measure now, and the milestones to watch in 2026.

Two milestones in 2025 moved organ cryopreservation from elegant physics to practical engineering: a 10-day pig kidney transplant after cryostorage and liter-scale nanowarming that heats human-sized volumes uniformly. Here is what changed, why it matters, and what comes next.

A wave of 2025 breakthroughs is pushing thymus preservation and regeneration from lab to clinic. Here is why immunosenescence is the next big lever for healthspan, what to watch over the next year, and how to fast-track the right biomarkers.

A May 2025 single-blind randomized trial from the Buck Institute and Circulate Health reports that therapeutic plasma exchange, especially when paired with intravenous immunoglobulin, shifted multi-omics biological age in older adults. Here is what changed, why it matters, and how this could enter clinics without outrunning the evidence.

Mitochondrial base editing moved from clever biology to an injectable therapeutic candidate in 2025. See the new editors, in vivo delivery data, and a pragmatic first-in-human plan aimed at aging tissues.

In September 2025, OHSU researchers reported human eggs made from skin cells and then fertilized in vitro. This review explains what was achieved, why it could extend reproductive longevity, the safety and regulatory gates ahead, and a realistic path to first pilots.

Japan has moved tooth regeneration from lab promise to the clinic. Toregem BioPharma’s anti-USAG-1 antibody, TRG-035, has orphan status and is now in first-in-human testing, opening a new path beyond dentures and implants.

2025 marked the year xenotransplantation left the lab. The FDA cleared the first human trials of gene-edited pig kidneys, and one recipient lived nearly nine months with a single graft. Here is how trials, safety guardrails, and manufacturing are turning a moonshot into medicine.

Fresh 2025 evidence moves CHIP from risk marker to modifiable target. ESC data link low-dose colchicine to slower TET2 clone growth, an NIH-backed canakinumab trial is enrolling, CKD ties sharpen risk, and JAMA Cardiology cautions against aspirin for primary prevention.

On October 22, 2025, Moderna ended its congenital CMV vaccine program after a failed primary endpoint. The loss points to a bigger win: treating CMV as a modifiable driver of immunosenescence with vaccines, T cells, and antivirals built for older adults.

In 2025, St. Jude’s SEN-SURVIVORS study gives senolytics a clean real-world test in adults who survived childhood cancer. If brief pulses of dasatinib plus quercetin or fisetin speed gait and lower T-cell p16INK4a, aging biology becomes a treatable target.

In 2025, PCSK9 base editing crossed from moonshot to near-term prevention. FDA milestones, first human data, and Lilly's move for Verve point to single-infusion cholesterol control.